IBX Secures Firm Commitments for $3.75m for Clinical Trial
Open PDF
| Stock | Imagion Biosystems Ltd (IBX.ASX) |
|---|---|
| Release Time | 25 Jun 2026, 9:28 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Imagion Secures $3.75m for HER2+ Breast Cancer Trial
Key Points
- Imagion Biosystems secures $3.75m in firm commitments
- Capital to fund Phase 1b/2 clinical trial
- FDA approval received for MagSense® imaging agent
Full Summary
Imagion Biosystems Limited (ASX: IBX) has secured $3.75 million in firm commitments to fund the commencement of its Phase 1b/2 clinical trial for the MagSense® HER2 imaging agent. The capital raising, led by CPS Capital, follows FDA clearance of the Investigational New Drug (IND) application. The funds will support trial activation, drug manufacturing, IP development, and collaborations with MRI experts. The trial is expected to begin patient recruitment in Q3 2026.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In